Abstract
H ealthcare costs can be significantly reduced by eradicating Helicobacter pylori in patients with duodenal ulcers, compared with the costs associated with providing antisecretory therapy only. 1 This was the conclusion of the Gastrointestinal Utilization Trial (GUT) that was presented at the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy [ New Orleans, US; September 1996 ]. GUT is the first prospective study to look at the costs associated with treating patients with duodenal ulcer. *
This is a preview of subscription content, log in via an institution to check access.
Additional information
1. Sonnenberg A, et al. Cost-impact of clarithromycin plus omperazole compared to traditional therapies for treatment of H. pylori associated duodenal ulcers. Late-Breaker Abstracts: 36th Interscience Conference on Antimicrobial Agents and Chemotherapy: 11, 18 Sep 1996
* A brief synopsis of the results was reported in Pharmaco-Economics & Outcomes News 85: 9, 26 Oct 1996; 800478594
Rights and permissions
About this article
Cite this article
Higgins, G., Todd, C. Eradicating H. pylori infection makes financial sense. Pharmacoecon. Outcomes News 88, 3–4 (1996). https://doi.org/10.1007/BF03295915
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF03295915